Targeting neglected kinases for new breast cancer therapies

针对被忽视的激酶进行新的乳腺癌疗法

• 批准号: 10009716
• 金额: $ 33.03万
• 依托单位: STINGRAY BIO LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10009716
• 关键词: Targeting; neglected; kinases; new; breast

Our new company is developing novel medicines for breast and other cancer types. We collaborate with leading university researchers, leveraging their knowledge and expertise to target a previously unaddressed cancer susceptibility. We are creating the first medicines tailored to a specific defect in cancer, building on a validated strategy to modulate protein kinases, a previously successful strategy used to treat a range of cancers.Our grant plan will expand on the original scientific foundation, grow our research team and drug development activities, and build our company skillsets and capabilities through partnerships with other cutting-edge businesses.Successful early drug development is resource-intensive, and our plan is built to secure a valuable patent portfolio and robust business capabilities. Our ongoing research is designed to deliver success through efficient planning and aims to achieve goals that will expand the size and sophistication of our company efforts. We plan to support cancer patients in need, through identification and delivery of novel therapies. Success will increase our product value, making it attractive for further investment and collaboration with global pharmaceutical companies.

我们的新公司正在开发用于乳腺癌和其他癌症类型的新药。我们与领先的大学研究人员合作，利用他们的知识和专业知识来瞄准以前未解决的癌症易感性。我们正在开发第一种针对癌症特定缺陷的药物，建立在经过验证的调节蛋白激酶的策略基础上，这是一种用于治疗一系列癌症的成功策略。我们的资助计划将在原有的科学基础上扩大，发展我们的研究团队和药物开发活动，并通过与其他尖端企业的合作伙伴关系建立我们公司的技能和能力。成功的早期药物开发是资源密集型的，我们的计划旨在确保有价值的专利组合和强大的业务能力。我们正在进行的研究旨在通过有效的规划取得成功，并旨在实现扩大公司规模和复杂性的目标。我们计划通过识别和提供新型疗法来支持有需要的癌症患者。成功将增加我们的产品价值，使其对进一步投资和与全球制药公司合作具有吸引力。